Renal Replacement Therapy Market Size Projected to Reach $3.21 billion by 2034 | 7.9%

According to Straits Research, the global renal replacement therapy market size was valued at $1.62 billion in 2025 and is projected to grow from $1.75 billion in 2026 to $3.21 billion by 2034, registering a CAGR of 7.9% during the forecast period 2026–2034.

Renal replacement therapy was introduced in the late 1970s.Burton introduced the term hemofiltration in 1976 and conducted the first multicenter trial to test its accuracy and effectiveness in the same year. Continuous arteriovenous hemofiltration (CAVH) was adopted in 1977 to treat patients with acute renal failure.In addition, CAVH also can preserve hemodynamic stability in critically illpatients.

Kidney disease is now recognized as an endemic problem of public health, affecting more than 850 million people across the globe. The Centers for Disease Control and Prevention (CDC) reported that chronic kidney disease (CKD) affects 15% of the U.S. adults, around 37 million people. Every day, in the U.S., about 13 patients die while waiting for a kidney transplant and renal replacement therapy. The demand for renal replacement therapies has enhanced as its products are helping surgeons to remove solutes in blood and tissue. Apart from this, rising cases of acute kidney injury (AKI), favorable reimbursement policies, and technological advancements in renal replacement therapy systems drive the market growth.

Impact COVID-19

The renal replacement therapy market is facing a shortage in the supply of products and consumables used in therapy due to the coronavirus outbreak. The market is estimated to witness revenue loss due to declining inpatient hospital services for renal replacements as most of the beds are occupied by COVID-19 patients. However, Fresenius Medical Care announced plans to assemble a national pool of 150 dialysis machines, which can be deployed to U.S. hospitals.

Key Highlights

• The renal replacement therapy market was valued at $1.75 billion in 2026 and is expected to grow with a CAGR of 7.9% on account of the growing prevalence of renal diseases and the surging geriatric population
• The consumable segment dominates the market on account of their high replacement rate
• The continuous venovenous hemofiltration (CVVH) segment holds sthe largest market share on account of increasing incidences of fluid overload cases.
• North America dominates the renal replacement therapy market as the region is backed by the presence of increasing demand for RRT procedures and technologically advanced products

Market Segments

1. By Modality
   1. Peritoneal Dialysis
   2. Continuous Renal Replacement Therapy (CRRT) 
   3. Hemodialysis
   4. Others
2. By End-User
   1. Hospitals
   2. Dialysis Center
   3. Home care
   4. Others